## **Accepted Manuscript**

Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality? A critical question that we are only just beginning to answer


Joel M. Gelfand, MD MSCE

PII: S0190-9622(18)30500-0

DOI: 10.1016/j.jaad.2018.03.046

Reference: YMJD 12435

To appear in: Journal of the American Academy of Dermatology



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**ACCEPTED MANUSCRIPT** 

**Invited Commentary** 

Does biologic treatment of psoriasis lower the risk of cardiovascular events and

mortality? A critical question that we are only just beginning to answer

Joel M Gelfand, MD MSCE

Professor of Dermatology, Professor of Epidemiology

Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit

Director, Psoriasis and Phototherapy Treatment Center

University of Pennsylvania Perelman School of Medicine

3400 Civic Center Boulevard

7<sup>th</sup> Floor, South Tower Office # 730

Philadelphia, PA 19104

Joel.Gelfand@uphs.upenn.edu

Word count 918

Reference count: 8

Funding: JMG is supported by NIH/NIAMS K24-AR064310

Disclosure: Dr. Gelfand served as a consultant for BMS, Boehringer Ingelheim, GSK, Janssen

Biologics, Menlo Therapeutics, Novartis Corp, Regeneron, Dr Reddy's labs, UCB (DSMB),

Sanofi and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the

University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho

Dermatologics, and Pfizer Inc.; and received payment for continuing medical education work

related to psoriasis that was supported indirectly by Lilly and Ortho Dermatologics. Dr. Gelfand

is a co-patent holder of resiguimod for treatment of cutaneous T cell lymphoma. Dr Gelfand is a

Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society

for Investigative Dermatology.

1

## Download English Version:

## https://daneshyari.com/en/article/8714959

Download Persian Version:

https://daneshyari.com/article/8714959

<u>Daneshyari.com</u>